A549

A549 (Lung Adenocarcinoma CDX Model) 

The A549 lung adenocarcinoma cell line was established from a male patient with alveolar adenocarcinoma. It carries a KRAS codon 12 mutation, a common driver in non-small cell lung cancer (NSCLC). A549 is one of the most widely used lung cancer models in oncology research. Its reproducibility makes it a global standard in NSCLC preclinical studies. 

Key Features: 

• Derived from alveolar adenocarcinoma of the lung. 

• KRAS codon 12 mutation. 

• Maintains epithelial morphology. 

• Popular NSCLC research model. 

Applications: 
A549 supports drug discovery programs across NSCLC, from chemotherapy evaluation to targeted therapy testing. Researchers use it for biomarker discovery and drug delivery research. It is also applied in mechanistic studies of lung cancer biology. Its consistent tumorigenicity ensures reproducibility in preclinical work.